Palisade Bio has used a large crossover financing to convert a former going-concern microcap into a funded Phase Two company whose entire equity story now sits on one gut-targeted oral program. The June quarter closed the regulatory work for a global ulcerative colitis study and kept a parallel Crohn’s application on the calendar. The market is no longer asking whether the issuer can pay for a first efficacy trial. It is asking whether a locally activated PDE4 prodrug can produce a clean remission signal in a crowded oral IBD field after only open-label work in a handful of patients.
Cash of $125 million at mid-year is the load-bearing fact. That pile, leftover from last October’s $138 million raise, is what management presents as enough to carry both Phase Two programs through primary readouts and still leave a short cushion. Enterprise value on basic shares sits near $152 million after subtracting cash, a modest option premium for a dual-indication IBD asset. The counterargument is that the human efficacy file is still five ulcerative colitis patients and five fibrostenotic Crohn’s patients, all open label, and that overhead plus stock-based pay jumped as the company professionalized.
The June quarter’s $11 million operating loss is the first print of a Phase Two cost base, not a finished run rate. First-patient screening in ulcerative colitis is the near-term clock. The Crohn’s application later this year is the second. Does a funded, single-asset oral IBD company deserve more than a cash-plus-option multiple before any controlled data exist?